- 1.
Medhus S, Mordal J, Holm B et al. A comparison of symptoms and drug use between patients with methamphetamine associated psychoses and patients diagnosed with schizophrenia in two acute psychiatric wards. Psychiatry Res 2013; 206: 17–21. [PubMed][CrossRef]
- 2.
World Health Organization. The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines. 2. utg. Geneva: World Health Organization, 2004.
- 3.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders 5th ed. Washington, DC: American Psychiatric Association, 2013.
- 4.
Mathias S, Lubman DI, Hides L. Substance-induced psychosis: a diagnostic conundrum. J Clin Psychiatry 2008; 69: 358–67. [PubMed][CrossRef]
- 5.
Rognli EB, Taipale H, Hjorthøj C et al. Annual incidence of substance-induced psychoses in Scandinavia from 2000 to 2016. Psychol Med 2022; 0: 1–10. [PubMed][CrossRef]
- 6.
Engh JA, Bramness JG. Psychosis relapse, medication non-adherence, and cannabis. Lancet Psychiatry 2017; 4: 578–9. [PubMed][CrossRef]
- 7.
van der Steur SJ, Batalla A, Bossong MG. Factors Moderating the Association Between Cannabis Use and Psychosis Risk: A Systematic Review. Brain Sci 2020; 10: 97. [PubMed][CrossRef]
- 8.
Angrist BM, Gershon S. The phenomenology of experimentally induced amphetamine psychosis–preliminary observations. Biol Psychiatry 1970; 2: 95–107. [PubMed]
- 9.
Hjorthøj C, Starzer MSK, Benros ME et al. Infections as a risk factor for and prognostic factor after substance-induced psychoses. Am J Psychiatry 2020; 177: 335–41. [PubMed][CrossRef]
- 10.
Kendler KS, Ohlsson H, Sundquist J et al. Prediction of Onset of Substance-Induced Psychotic Disorder and Its Progression to Schizophrenia in a Swedish National Sample. Am J Psychiatry 2019; 176: 711–9. [PubMed][CrossRef]
- 11.
Løberg EM, Helle S, Nygård M et al. The Cannabis Pathway to Non-Affective Psychosis may Reflect Less Neurobiological Vulnerability. Front Psychiatry 2014; 5: 159. [PubMed]
- 12.
Murrie B, Lappin J, Large M et al. Transition of Substance-Induced, Brief, and Atypical Psychoses to Schizophrenia: A Systematic Review and Meta-analysis. Schizophr Bull 2020; 46: 505–16. [PubMed][CrossRef]
- 13.
Rognli EB, Heiberg IH, Jacobsen BK et al. Transition from substance-induced psychosis to schizophrenia spectrum disorder or bipolar disorder. JAMA Psychiatry 2023; godkjent for publisering.
- 14.
Mitchell AJ. Reluctance to disclose difficult diagnoses: a narrative review comparing communication by psychiatrists and oncologists. Support Care Cancer 2007; 15: 819–28. [PubMed][CrossRef]
- 15.
Helsedirektoratet. Utredning, behandling og oppfølging av personer med psykoselidelser. Oslo: Helsedirektoratet, 2013.
- 16.
Syse A. Strafferettslig utilregnelighet – Utilregnelig innhold og nærmest utilregnelig prosess. I: Asland J, Syse A, Fredwall K et al., red. Livsfellesskap – Rettsfellesskap Tone Sverdrup 70 år. Oslo: Gyldendal, 2021.
- 17.
Lovdata. Lov om straff (straffeloven). https://lovdata.no/dokument/NL/lov/2005-05-20-28 Lest 21.12.2022.
- 18.
Frøberg T. De nye reglene om strafferettslig skyldevne. Lov og Rett 2020; 59: 167–84. [CrossRef]
- 19.
Norges Høyesterett. HR-2010-00488-A, (sak nr. 2009/1981). https://www.domstol.no/globalassets/upload/hret/avgjorelser/2010/saknr2009-1981anonymisert.pdf Lest 21.12.2022.
- 20.
Justis- og beredskapsdepartementet. Endringer i straffeloven og straffeprosessloven mv. (skyldevne, samfunnsvern og sakkyndighet). https://www.stortinget.no/no/Saker-og-publikasjoner/Saker/Sak/?p=69169 Lest 21.12.2022.
()
Spennende artikkel
26.02.2023Jeg håper denne artikkelen kan endre praksis etter akuttinnleggelse og kanskje bidra til at flere får bedre oppfølgning. Dessverre vet jeg det er vanskelig så lenge det er frivillig og pasienten ikke selv er motivert. Dette er nok spesielt krevende for unge og…